Jeito Capital, based in Paris, announcement the final close of his first fund, Jeito I. The initial target was 500 million euros but reached 534 million euros (630 million US dollars). It is the largest venture capital fund in Europe focused on life sciences.
So far, the fund’s investments include French companies SparingVision and InnoSkel. SparingVision is a genomic ophthalmology company and InnoSkel targets rare skeletal diseases. Additional investments include Holland Neogene Therapeutics, an anticancer company, UK-based Pulmocide for severe respiratory diseases, and Alentis Therapeutics, a Franco-Swiss company specializing in fibrosis and related cancers.
Investors in the Jeito I fund included the European Investment Fund (EIF), the American pension fund Teacher Retirement System of Texas (TRS), its very first investment in a European biotech fund, and Temasek, an investment firm. in Singapore-based Life Sciences. .
Jeito Capital was founded and managed by Rafaèle Tordjman and was launched in January 2020. Tordjman joined Sofinnova Partners’ Life Sciences as research analyst in November 2001. Two years later, she became Investment Manager. Before Sofinnova, she was a researcher at the National Institute of Medical Research (INSERM) at the Cochin Hospital in Paris, and before that, a Doctor of Medicine specializing in clinical hematology and internal medicine.
Other managing partners include Sabine Dandiguian and Rachel Mears.
The first funding round was 200 million euros with the support of Aviva, AXA, the Public Investment Bank (BPI), BNP Paribas Fortis, La Caisse des Dépôts et des Consignations (CDC), CNP Assurances, Pro Construction, etc. The Parisian company Sanofi has chosen Jeito for its very first investment in a French fund. Sanofi has paid 50 million euros into the fund.
“We are extremely proud to have closed Jeiti I, making it the largest European fund dedicated to the life sciences sector,” said Tordjman. “This has surpassed our original target and attracted a group of leading and diverse global investors, a testament to Jeito’s unique investment model and team. “
Jeito Capital also has Activities in the United States, with a partner living in New York. The main focus is on Europe, but wants global reach.
Jeito I will fund between 12 and 15 European life science companies. Tordjman was given the job improvement of the French biotech ecosystem by the French government in July 2021.
Jeito plans to invest up to $ 100 million (US) in a specific holding company and is actively seeking to invest in autoimmune diseases and inflammatory disorders.
Sabine Dandiguian, Managing Partner of Jeito Capital, declared: “This exceptional fundraising success confirms Jeito’s investment model driven by Rafaèle Tordjman. I am very proud to have been part of this multi-talented team from the very beginning which, thanks to its expertise at all stages of the company’s development, is able to discover and support the best start-ups. of scientific quality in Europe, with a reach. Thanks to Jeito’s dynamic and collaborative team, we have already developed a high-quality transaction flow pipeline. We look forward to realizing our shared ambitions and making a meaningful and meaningful difference in the lives of patients. “